The aim of this study was to evaluate the additional value of dimeric inhibin-A serum concentration in second trimester multiple-marker screening tests for pregnancies affected by Down's syndrome. We anticipated that second trimester maternal serum dimeric inhibin-A concentrations would be altered in pregnancies complicated by fetal Down's syndrome and that dimeric inhibin-A would perform better than one of the three substances analysed in the multiple-marker screening test currently in use. A total of 1156 serum samples were screened for dimeric inhibin-A in parallel with the routine classic triple test screening programme performed on a random obstetric population. Classic triple test performance was compared with detection rates obtained after substitution of unconjugated oestriol by inhibin-A and with the performance of inhibin-A and α-fetoprotein alone. Absolute dimeric inhibin-A maternal serum concentrations of Down's syndrome pregnancies were indeed significantly higher than those of normal pregnancies in our screened population. The performance of dimeric inhibin-A in combination with the multiple-marker screening test, however, is limited because of its strong correlation with intact human chorionic gonadotrophin. Key words: dimeric inhibin-A/Down's syndrome/screening/ second trimester Introduction Merkatz et al. (1984) reported that pregnancies complicated by fetal autosomal trisomies are characterized by low maternal serum α-fetoprotein (MSAFP) concentrations. In 1987, Cuckle et al. published the first results on screening for Down's syndrome using AFP and maternal age. Numerous other pregnancy-associated maternal serum markers for fetal trisomy 21 (Down's syndrome) have been evaluated since. It has been established that human chorionic gonadotrophin (HCG) concentrations are higher and oestriol concentrations are lower in Down's syndrome pregnancies. These three parameters (AFP, HCG and free oestriol), in addition to maternal age, are used routinely in risk calculation programmes for second
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reported that pregnancies complicated by fetal autosomal trisomies are characterized by low maternal serum α-fetoprotein (MSAFP) concentrations. In 1987, Cuckle et al. published the first results on screening for Down's syndrome using AFP and maternal age. Numerous other pregnancy-associated maternal serum markers for fetal trisomy 21 (Down's syndrome) have been evaluated since. It has been established that human chorionic gonadotrophin (HCG) concentrations are higher and oestriol concentrations are lower in Down's syndrome pregnancies. These three parameters (AFP, HCG and free oestriol), in addition to maternal age, are used routinely in risk calculation programmes for second 744 © European Society for Human Reproduction and Embryology trimester Down's syndrome screening. Multiple-marker screening tests for fetal Down's syndrome detect~60% of all Down's syndrome cases in women aged Ͻ35 years (screen-positive rate ϭ 3.8%) and 75-89% in women aged ജ35 years (screenpositive rate ϭ 25%) Cheng et al., 1993) . It is not surprising, therefore, that prenatal screening for Down's syndrome has become an important and established part of modern prenatal care in Belgium.
Efforts to improve biochemical screening have centred on the search for better markers in order to either improve the Down's syndrome detection rate or reduce the false-positive rate. Numerous pregnancy-associated substances analysed in serum have been evaluated. Additional markers, such as progesterone (Kratzer et al., 1991) , pregnancy-associated plasma protein A (Brambati et al., 1993) , schwangerschaftsprotein 1 (Brock et al., 1990) and placental alkaline phosphatase (Ind et al., 1993) , have been evaluated but without success.
Inhibin, a heterodimeric protein with a molecular weight of 32 000, has emerged recently as a promising candidate. It is composed of one α-subunit and one of two related β-subunits (β-A or β-B), and is produced by the syncytiotrophoblast of human placenta (Petraglia et al., 1987) . Of the bioactive dimeric inhibins, only inhibin-A is present in maternal serum during pregnancy (Riley et al., 1996) . Three early studies, depending on assays using antibodies directed against epitopes only on the α-subunit, reported conflicting immunoreactive inhibin concentrations in maternal serum from second trimester as well as first trimester pregnancies affected by Down's syndrome (Van Lith et al., 1992; Spencer et al., 1993; Cuckle et al., 1994a) . However, an estimation of dimeric inhibin-A concentrations using a two-site immunoassay with monoclonal antibodies has reported an additional value in the detection of Down's syndrome in two recent studies (Aitken et al., 1996; Wallace et al., 1996) .
These studies are all retrospective and have been performed on small series. In a preliminary trial we analysed 260 serum samples for dimeric inhibin-A and 1156 serum samples in a second trial, in parallel with our routine second trimester Down's syndrome screening programme. We attempted to confirm the promising preliminary inhibin-A data for second trimester Down's syndrome screening in a larger series and in routine day-to-day screening procedures.
Materials and methods
The Down's syndrome screening programme in our laboratory includes AFP, HCG and free oestriol as biochemical markers. Second trimester serum samples were analysed for AFP, β-HCG and unconjugated oestriol using isotopic assays (I 125 Screening for Down's syndrome is performed twice a week (~80 samples each run) and all assays are performed in duplicate. For risk calculations we used the algorithm published by Palomaki et al. (1992;  Foundation for Blood Research, Box 190, Scarborough, ME 04074, USA), which can be used freely if acknowledged as such. After each run, a quality control program calculated the means and SD for each parameter. MoM values were improved and controlled each month with an exponential regression analysis. Correction was performed for weight and smoking. In cases of multiple pregnancy (twins), we used the correction factors published by Wald (1991) . The obstetric population from an ethnic point of view was considered to be homogeneous Caucasian because most other ethnic groups refused triple testing for religious reasons. Mean Ϯ SD maternal age distribution was 32 Ϯ 1 years. In the affected pregnancies group (n ϭ 18) all mothers were multiparous. In the unaffected (control) group the mean Ϯ SD maternal age was 28 Ϯ 1 years. The group consisted of 20% nullipara and 80% multipara. In this control group 2% of newborn babies suffered from major or minor neonatal complications. Therefore it was highly unlikely that the control group was biased for factors that would raise inhibin-A or HCG concentrations at 16 weeks of pregnancy, as was suggested recently for hypertensive pregnancies at 29 weeks (Muttukrishna et al., 1997) .
To evaluate the discriminative power of dimeric inhibin-A, we analysed 260 serum samples stored at -20°C, including 14 samples from Down's syndrome pregnancies, in the first retrospective pilot trial.
Reagents for dimeric inhibin-A were commercially available from Serotec Ltd (Kidlington, UK; product code MCA 127 3KZZ). Dimeric inhibin-A was measured by a two-site enzyme-linked immunosorbent assay which utilised an immobilized anti-βA inhibin subunit monoclonal antibody as the capture antibody. The second or detection antibody was a monoclonal antibody specific for the α-subunit of inhibin and was coupled to alkaline phosphatase. The assay was rather cumbersome and time-consuming (2.5 days), and therefore not ideal for routine day-to-day large-scale population screening purposes. In the second trial on 1156 serum samples we modified the original assay (with the support of N.Groome) so that results were obtained on the same working day (duration time of the assay Ϯ6 h). In this partially prospective trial, the former affected serum samples, as well as four new affected ones, were reintroduced and reanalysed at random, along with incoming routine screening samples. The sensitivity of the modified assay was 0.3 pg/tube (4 pg/ml); the variation within and between assays was 3.9 and 18.7% respectively.
Our reference values in the second trimester were in agreement with those in the leaflet of the kit (Table I) .
Statistical analyses were performed using a software program (NCCS 6.0; NCSS, Kaysville, UT, USA). The results were presented as means Ϯ SD. An unpaired t-test was used to compare pairs of means; when necessary, the unequal variance of data was taken into account.
Results
In the preliminary pilot trial, 260 samples from second trimester pregnancies (12-20 weeks), including 14 samples from trisomy 745 Aitken et al. (1996) . 21 pregnancies, were analysed for dimeric inhibin-A. There was only a minor fluctuation in the absolute dimeric inhibin-A concentrations in the second trimester of pregnancy. The mean concentration in unaffected pregnancies (n ϭ 246) was 167 pg/ml, while in affected pregnancies (n ϭ 14) the value was 375 pg/ml. In Table II , dimeric MoM values (mean Ϯ SD) for affected and unaffected pregnancies are shown for both trials. Dimeric inhibin-A MoM concentrations were higher in affected pregnancies at a significance of P ϭ 0.01 for the pilot trial. There was only a small overlap between affected and unaffected pregnancies. In Table III detection results are shown for the two trials using three different methods. The second column shows the results for AFP ϩ inhibin-A, while in the last column free oestriol is substituted by the dimeric inhibin-A results in the algorithm for the triple-risk calculation. Using a cut-off value of 1/270, we missed five trisomy 21 pregnancies in our routine classic triple-test screening programme; if we used the cut-off value of 1/300 we missed only three pregnancies (first column). With AFP and dimeric inhibin-A as screening parameters (second column), only two affected pregnancies were missed with the cut-off value of 1/270 and only one with a cut-off value of 1/300. On inclusion of HCG and with a cut-off value of 1/270, three affected pregnancies were missed. The results we obtained in this small series were promising and encouraging, but there was still a high falsepositive rate (13%) and therefore the associated risk of an unnecessary amniocentesis was high.
Following the results from our first trial, in the second trial we increased the number of samples from 260 to 1156, including 18 affected pregnancies. Figure 1 depicts the distribution of dimeric inhibin-A MoM concentrations between weeks 12 and 20 of pregnancy in the second trial for normal and affected pregnancies. All the dimeric inhibin-A results ( Figure  1) were obtained using the modified enzyme-linked immunosorbent assay test (short incubation times) described above. Inhibin-A MoM concentrations were significantly higher (P Ͻ 0.001) in trisomy pregnancies than in unaffected pregnancies (Table II) , but absolute concentrations were lower in our study than in other published research .
In analogy with the then current publications on dimeric inhibin-A and Down's syndrome screening, in our second trial we focused on a 5% false-positive ratio rather than a fixed cut-off risk value (Table III) .
The incorporation of dimeric inhibin-A in the algorithm (columns 2 and 3) resulted in totally different combined risk values in comparison with the classic triple test. In contradiction to the first trial, the combination of AFP ϩ intact HCG ϩ dimeric inhibin-A scored better than the combination of AFP ϩ inhibin-A alone, reaching a sensitivity of 66.7% and a specificity of 94.7% (Table III ; column 3).
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Discussion
Results of the second trial are highly representative of results from day to day practice. From a statistical viewpoint, however, ideally a cohort of at least 18 000 samples is needed when 18 Down's syndrome pregnancies are included (a risk of 1/1000 in the second trimester of pregnancy). Compared with the literature, our number of controls is high in comparison with the number of affected pregnancies included (Table IV) .
Most studies in the literature are retrospective and could tend to overestimate performance because the ideal conditions of a study may not apply in practice. One study obtained a higher prediction rate (75% at a 5% false-positive rate) by adding inhibin-A to the AFP and β-HCG combination in the first trimester screening. They found a strong correlation between inhibin-A and intact HCG, which excluded the use of intact HCG ϩ inhibin-A in the algorithm (two non-independent variables). We confirmed this correlation (r ϭ 0.507) in the second trimester and thus were forced to omit HCG from the algorithm, which decreased the detection ratio (P ϭ 0.095) significantly in our risk calculation. Wald et al. (1997) recently reduced their estimated detection rate from 78 to 75% for a 5% false-positive rate using the quadruple test (AFP, unconjugated oestriol, free β-HCG, inhibin-A with maternal age, maternal weight adjustment and an ultrasound scan examination to estimate gestational age). They revised their underestimated SD of inhibin-A in pregnancies with Down's syndrome. This highlights the importance of a laboratory's own assay standards for inhibin and explains why our inhibin serum concentrations may have slightly different values especially for our modified 'short' assay. We confirmed that dimeric inhibin-A is not predictive for other chromosomal anomalies, and the inclusion of inhibin-A in our multi-marker screening programme did not contribute to the detection of trisomy 18 (n ϭ 4; inhibin-A MoM ϭ 0.61 Ϯ 0.16). We also confirmed the significantly higher inhibin-A MoM concentrations in trisomy 21 pregnancies. Wallace et al. (1996) reported that inhibin-A alone offered a detection rate of 62% and could detect cases previously undetected by routine screening in the second trimester. We counted two patients with a false-negative result on the inhibin-A triple test who were, however, detected with the classic triple test; in these cases there was no advantage to using inhibin-A in triple testing. However we could confirm the theoretical advantage of the use of dimeric inhibin-A above other current parameters (especially unconjugated oestriol) because of its very minor fluctuations between 14 and 18 weeks of pregnancy (Table I) . Therefore inaccuracies in estimating the gestational stage of pregnancy would have minor consequences in the calculation of inhibin-A MoM concentrations.
Several authors have suggested that other factors which could influence maternal serum MoM concentration, such as vaginal bleeding (Cuckle et al., 1994b) , ovulation induction (Heinonen et al., 1996; Ribbert et al., 1996) , increasing gravidity and parity (Mooney et al., 1995) and smoking (Cuckle et al., 1992) , should be taken into account.
We rigorously recorded these factors (Table V) and noticed a highly significant influence of smoking, which therefore constitutes a possible correction factor in future protocols. Our results are consistent with previous retrospective studies with respect to some but not all results. Therefore an enlarged multicentre study over a longer period of time is necessary before making firm conclusions about the use of dimeric 747 inhibin-A in second trimester Down's syndrome screening programmes. We believe that the data are not yet sufficiently consistent to incorporate inhibin-A in day-to-day laboratory screening procedures.
